SCHEMBL23182928

SCHEMBL23182928

O=C(O)C1CC1Oc1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ LSS P48449 1/20 0.44
▸ FFAR4 Q5NUL3 3/20 0.42
▸ SLC6A4 P31645 3/20 0.41
▸ SLC6A2 P23975 2/20 0.41
▸ SLC6A3 Q01959 2/20 0.41
▸ S1PR5 Q9H228 1/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ ATF4 P18848 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ PPARA Q07869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27878721 0.83 FFAR4 (0.44) FFAR4SLC6A4SLC6A2SLC6A3MEN1
SCHEMBL24658820 0.82 RXRA (0.39) ALDH1A1LMNAFFAR4POLBEPHX2
SCHEMBL28750680 0.79 ALDH1A1 (0.47) ALDH1A1FFAR4KMT2A
SCHEMBL23039979 0.79 ALDH1A1 (0.47) ALDH1A1FFAR4KMT2A
SCHEMBL23040236 0.79 FFAR4 (0.38) ALDH1A1FFAR4MEN1KMT2A
SCHEMBL23039953 0.79 FFAR4 (0.38) ALDH1A1FFAR4MEN1KMT2A
SCHEMBL3802037 0.78 CTSS (0.40) ALDH1A1LMNAFFAR4MAPTEPHX2
SCHEMBL3794151 0.78 CTSS (0.40) ALDH1A1LMNAFFAR4MAPTEPHX2
SCHEMBL29270941 0.77 FFAR4 (0.39) ALDH1A1FFAR4KMT2A
SCHEMBL29270939 0.77 FFAR4 (0.39) ALDH1A1FFAR4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-01 — — US disclosed
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-01 — — US disclosed
EP-3634952-A1 CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-04-15 — — EP disclosed
WO-2018225093-A1 CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors ATF4, ATF1, XBP1 ALDH1A1 2325/4885LMNA 3667/4885LSS 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback